Evidence map›Paper›PMID 31790375›Full record

ArticleJournal of hypertension2020

Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure.

James E Sharman, Eoin O'Brien, Bruce Alpert, Aletta E Schutte, Christian Delles, Michael Hecht Olsen, Roland Asmar, Neil Atkins, Eduardo Barbosa, David Calhoun and 27 more

Registry-linked trialAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05393401 (Photoplethysmographic Measurements of Pulse Wave Velocity), which is not on this map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05393401 narecruitingnot on this mapstarted 2022, after this paper: background citation

Photoplethysmographic Measurements of Pulse Wave Velocity (PWV) and Blood Pressure (BP) MEPPAVOP

TypeinterventionalSponsorUniversity Hospital, GrenobleRan2022 to 2026Enrolled27ConditionsHealthy VolunteersArmsVOP1k
3 · Its place in the literature

Who cites it

68 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Global trends in hypertension prevalence, awareness, treatment, and control.Current opinion in nephrology and hypertension · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Current status of the use of validated home blood pressure monitoring devices among Korean patients with hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. In-office and out-of-office blood pressure measurement.Journal of human hypertension · 2024
    Review
  17. Article
  18. Article
  19. Revista panamericana de salud publica = Pan American journal of public health · 2024
    Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors.

James E SharmanMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia The Conway Institute, University College Dublin, Dublin, Ireland University of Tennessee Health Science Center, Memphis, Tennessee, USA Hypertension in Africa Research Team, Medical Research Council Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK Department of Internal Medicine, Holbaek Hospital, Holbaek Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, University of Southern Denmark, Odense, Denmark Foundation-Medical Research Institutes, Geneva, Switzerland Medaval Ltd., Dublin, Ireland Hypertension League of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil Vascular Biology and Hypertension Group, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Medicine, Physiology and Pharmacology and Community Health Sciences, O'Brien Institute for Public Health and Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia American Heart Association, Dallas, Texas, USA Sydney Medical School, University of Sydney and Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970 and University Paris Descartes, Paris, France FOSCAL, Instituto Masira, Facultad de Ciencias de la Salud, UDES, Bucaramanga, Colombia Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Oxford, UK Cardiovascular & Hormonal Research Laboratory, Department of Cardiology & Kolling Institute, Royal North Shore Hospital and Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia Department of Non Communicable and Mental Health, Pan American Health Organization, Washington, District of Columbia Department of Medicine, University of Alberta, Edmonton, Alberta, Canada Studium Patavinum, University of Padova, Padua Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, IRCCS, San Luca Hospital Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy Imperial Clinical Trials Unit, Imperial College London, London, UK American Medical Association, Improving Health Outcomes, Chicago, Illinois Department of Medicine (Cardiology), Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York The James J. Peters VA Medical Center, Bronx, New York, USA Cardiology Unit, Department of Medicine, University of Padova, Town Hospital of Cittadella, Padova Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy Hypertension League, Department of Cardiology, Federal University of Goiás, Goiânia, Brazil Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China Steno Diabetes Center Copenhagen, Gentofte, Denmark Third Department of Medicine, Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Greece.
Eoin O'Brien
Bruce Alpert
Aletta E Schutte
Christian Delles
Michael Hecht Olsen
Roland Asmar
Neil Atkins
Eduardo Barbosa
David Calhoun
Norm R C Campbell
John Chalmers
Ivor Benjamin
Garry Jennings
Stéphane Laurent
Pierre Boutouyrie
Patricio Lopez-Jaramillo
Richard J McManus
Anastasia S Mihailidou
Pedro Ordunez
Raj Padwal
Paolo Palatini
Gianfranco Parati
Neil Poulter
Michael K Rakotz
Clive Rosendorff
Francesca Saladini
Angelo Scuteri
Weimar Sebba Barroso
Myeong-Chan Cho
Ki-Chul Sung
Raymond R Townsend
Ji-Guang Wang
Tine Willum Hansen
Gregory Wozniak
George Stergiou
Lancet Commission on Hypertension Group

Funding

Department of Health NIHR-RP-02-12-015
6 · The paper itself

Abstract

: The Lancet Commission on Hypertension identified that a key action to address the worldwide burden of high blood pressure (BP) was to improve the quality of BP measurements by using BP devices that have been validated for accuracy. Currently, there are over 3000 commercially available BP devices, but many do not have published data on accuracy testing according to established scientific standards. This problem is enabled through weak or absent regulations that allow clearance of devices for commercial use without formal validation. In addition, new BP technologies have emerged (e.g. cuffless sensors) for which there is no scientific consensus regarding BP measurement accuracy standards. Altogether, these issues contribute to the widespread availability of clinic and home BP devices with limited or uncertain accuracy, leading to inappropriate hypertension diagnosis, management and drug treatment on a global scale. The most significant problems relating to the accuracy of BP devices can be resolved by the regulatory requirement for mandatory independent validation of BP devices according to the universally-accepted International Organisation for Standardization Standard. This is a primary recommendation for which there is an urgent international need. Other key recommendations are development of validation standards specifically for new BP technologies and online lists of accurate devices that are accessible to consumers and health professionals. Recommendations are aligned with WHO policies on medical devices and universal healthcare. Adherence to recommendations would increase the global availability of accurate BP devices and result in better diagnosis and treatment of hypertension, thus decreasing the worldwide burden from high BP.

Indexed as

Blood Pressure DeterminationHumansHypertensionPractice Guidelines as TopicSphygmomanometers

Identifiers

PMID31790375
PMCPMC6919228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.